NCT03546842 · MORE INFO

Limitations, agreements, and source contact

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) · Source last updated 2020-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: ClinicalTrialsDisclosure@merck.com
organization: Merck Sharp & Dohme Corp.
phone: 1-800-672-6372
title: Clinical Trials Disclosure

Complete source fields

certain Agreement

other Details: If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: ClinicalTrialsDisclosure@merck.com
organization: Merck Sharp & Dohme Corp.
phone: 1-800-672-6372
title: Clinical Trials Disclosure

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice